Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Activity Description
The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer the potential to further optimize visual and anatomical outcomes for patients with these diseases. Furthermore, with the addition of newly approved therapies that have longer durations of action, sustained drug delivery systems, and emerging novel therapies, it can be challenging to stay abreast of the numerous and ongoing therapeutic advances. In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary to age-related macular degeneration can be integrated into individualized treatment paradigms for the optimal management of these patients. They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion.
Target Audience
The intended audience for this activity is US-based retina specialists and ophthalmologists involved in the management of patients with retinal diseases.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Describe how imaging and the use of new therapies for geographic atrophy secondary to age-related macular degeneration can fit into the treatment paradigm.
- Summarize innovations in imaging that can improve the diagnosis and management of retinal diseases.
- Recognize advances in imaging and treatment of retinal vein occlusion.
- Summarize innovations in imaging as well as in vitreoretinal surgery that can improve the diagnosis and management of retinal diseases.
Activity Chair
Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH
Faculty
David A. Eichenbaum, MD, FASRS
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
St. Petersburg, FL
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Professor of Surgery
University of Nevada, Reno School of Medicine
Reno, NV
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Professor of Ophthalmology With Tenure
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, TX
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 31, 2025, to January 30, 2026.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 of the 7 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
David A. Eichenbaum, MD, FASRS
Consultant: Alimera, Allergan, Amaros, Annexon, Apellis, Astellas, Bausch + Lomb, Coherus, Complement Therapeutics, Crinetics, EyePoint, Genentech, Harrow, Kodiak, Neurotech, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Opthea, Outlook, RecensMedical, Regeneron, Regenxbio, Revive, RetinAI, Samsara, Stealth, Tilack
Independent Research Contractor: 4DMT, Aerie/Alcon, Alexion, Allgenesis, Annexon, Astellas, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, Janssen, Kodiak, Kyowa Kirin, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, RecensMedical, Regeneron, Regenxbio, Roche, Stealth, Unity
Stock Options: Amaros, Revive
Individual Stocks (publicly traded): Janssen
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis, Aviceda, Beacon, Boehringer Ingelheim, Clearside, Complement Therapeutics, Exegenesis, EyePoint, Frontera, Genentech, Gyroscope, i-Lumen, IVERIC bio, Janssen, Kodiak, Kriya, Kyowa Kirin, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olive BioPharma, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, Revive, RevOpsis, Roche, Sanofi, Stealth BioTherapeutics, Thea, Unity Bio, Vanotech, Vial
Independent Research Contractor: 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, Eluminex, EyePoint, Exegenesis, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Kyowa Kirin, Neurotech, Ocular Therapeutix, Oxular, Regenxbio
Stock Options: Aviceda, Oculis, Opthea, Perfuse, PolyPhotonix, RecensMedical, RevOpsis, Vial
Board of Directors: Oculis
Rishi P. Singh, MD
Consultant: Alcon, Apellis, Bausch + Lomb, EyePoint, Genentech, IVERIC bio, Regenxbio, Regeneron, Zeiss
Independent Research Contractor: Janssen
Lejla Vajzovic, MD, FASRS
Advisor: Astellas, BioCryst, Clearside, Ocugen, Ocular Therapeutix, Regenxbio
Consultant: AbbVie/Allergan, Alcon, Alimera, Apellis, Bausch + Lomb, BVI, BMC, Clearside, Coherus, DORC, Genentech, Guidepoint, Gyroscope, IVERIC bio, Janssen/J&J Vision, Lexitas, Nanoscope, Novartis, Ocugen, Ocular Therapeutix, Ocular Surgical, OcuTerra, ONL Therapeutics, Outlook Therapeutics, Regeneron, Regenxbio
Speaker Contracted by Ineligible Company: AbbVie/Allergan, Alcon, Apellis, DORC, IVERIC bio, Ocular Surgical
Independent Research Contractor: AGTC, Alcon, Aldeyra, Apellis, Genentech, Gyroscope, Heidelberg Engineering, Janssen/J&J Vision, Novartis, Ocular Therapeutix, Regenxbio
Christina Y. Weng, MD, MBA
Royalties or Patent Beneficiary: Springer
Consultant: Alcon, Alimera, Allergan/AbbVie, Apellis, Astellas/IVERIC bio, DORC, EyePoint, Genentech, Novartis, Opthea, Regeneron, Regenxbio
Independent Research Contractor: Alimera, AGTC, DRCR Retina Network
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2025 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com